Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON, Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a...
Related Questions
What is the expected timeline for the Phase 2 trial results and subsequent regulatory milestones?
How will the FDA acceptance and upcoming trial affect Coya's valuation relative to other ALS-focused biotech companies?
What potential financial impact could arise if the Phase 2 trial demonstrates positive efficacy and safety outcomes?